Metabolic Peptides
GLP-3 RT
Research Grade≥99% PurityLyophilized
A triple agonist targeting GIP, GLP-1, and glucagon receptors for receptor binding research.
Dosage
$110.00
Quantity
Bundle & Save
We accept
Certificate of Analysis
Third Party Tested by Freedom Diagnostics
Frequently Bought Together
Bacteriostatic Water
10 ml
$10.00
GLP-2 TZ
10 mg
$85.00
NAD+
500 mg
$70.00
GHK-Cu
50 mg
$65.00
BPC-157
5 mg
$45.00
Melanotan II
10 mg
$55.00
Tesamorelin
10 mg
$85.00
TB-500
10 mg
$45.00
MOTS-c
10 mg
$75.00
Research Summary
GLP-3 RT
Published research data and clinical observations
🔬
Research Phase
Phase III trials enrolling
💉
Administration
Up to 12mg once weekly
🧬
Key Mechanism
GLP-1 + GIP + Glucagon
📄
Publications
NEJM + Lancet Phase II data
👥
Subjects Studied
Phase II clinical trials
What Makes GLP-3 RT Different?
The Science, Simplified
Three Receptors, One Molecule
Unlike GLP-1 (which targets 1 receptor) or GLP-2 (which targets 2), GLP-3 activates three different hormone receptors at once. Each receptor triggers a different metabolic pathway — and together, they deliver more powerful effects than any single-target approach.
GIP
Strongest
GIP Receptor
Glucose-dependent Insulinotropic Polypeptide
Helps release insulin
Improves fat metabolism
Enhances satiety
GLP-1
Moderate
GLP-1 Receptor
Glucagon-like Peptide-1
Reduces appetite
Slows digestion
Improves blood sugar
GCG
Targeted
Glucagon Receptor
The "Secret Weapon"
Burns liver fat directly
Increases energy burn
Lowers cholesterol
WHY GLUCAGON MATTERS
The Third Receptor Advantage
The glucagon receptor is what sets GLP-3 apart. In trials, researchers observed that activating this receptor:
Directly burns fat stored in the liver — which may explain why trial participants saw up to 86% reduction in liver fat.
GLP-1GLP-1 only
GLP-2GLP-1 + GIP
GLP-3GLP-1 + GIP + GCG
Peak weight loss across incretin generations
What Researchers Observed
24.2%
Mean body weight reduction (12mg)
Jastreboff et al. (NEJM, 2023), Phase II, 48 weeks
58%
83%
97%
88%
Key Milestones Achieved
93%
100% of 12mg group at 48 wks
83%
83% of 12mg group
82%
Rosenstock et al. (Lancet, 2023)
For context:The Phase II obesity trial (Jastreboff et al., NEJM, 2023, n=338) showed dose-dependent weight loss: 8.7% (1mg), 17.1% (4mg), 22.8% (8mg), and 24.2% (12mg) at 48 weeks vs 2.1% placebo. The T2D trial (Rosenstock et al., Lancet, 2023, n=281) showed HbA1c improvement of 2.2% and 16.9% weight loss at 36 weeks. GLP-3 RT is for research use only.
Compound Information
Technical specifications
❄️ Storage Requirements
Stability Information
Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
-20°C · 24+ months
Reconstituted
2-8°C · ~30 days
📋 Development Status
Where It Stands
Phase 3 ActiveResearch Use Only
DeveloperEli Lilly
Trial ProgramTRIUMPH
ResultsExpected 2026
Potential Approval~2027
This page summarizes published research for informational purposes only. These products are sold exclusively as research chemicals and are not intended for human consumption. Always consult peer-reviewed literature for complete study details.
Your Cart
Your cart is empty